The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

WHO has officially recommended twice-yearly injectable lenacapavir for HIV prevention, marking a major shift in global HIV ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK, said on Monday it has expanded its licensing deal with the Medicines Patent Pool to allow generic production of its long-acting ...

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

The World Health Organization (WHO) on Monday recommended countries to use the twice-a-year lenacapavir injection as an add ...

The World Health Organization (WHO) released today new guidelines recommending the use of injectable lenacapavir (LEN) twice ...

Lenacapavir, trialed in Uganda, offers 100% protection but will it reach those who need it most? Kampala, Uganda | RONALD ...

A landmark breakthrough in HIV prevention received final approval from the Food and Drug Administration last month. Gilead Sciences’ lenacapavir is so effective that global health leaders had started ...

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...